Haleon Stock (NYSE:HLN)
Previous Close
$9.12
52W Range
$8.65 - $11.28
50D Avg
$9.38
200D Avg
$9.74
Market Cap
$40.16B
Avg Vol (3M)
$8.53M
Beta
0.25
Div Yield
$0.19 (2.10%)
HLN Company Profile
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.